Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer

NCT01575522 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01575522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01575522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
July 31, 2013
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, her2/neu negative, progesterone receptor negative, recurrent breast carcinoma, stage iv breast cancer, triple-negative breast carcinoma